Sudeep Pharma Ltd

With every major technical indicator aligned to the upside, Sudeep Pharma Ltd surged to a fresh 52-week high of Rs 893.4 on 6 Jul 2026, marking a significant milestone in its price momentum despite a slight pullback on the day.

Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by a combination of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, signalling a potential uptrend in the stock’s price trajectory.

Surging to an all-time high of Rs 885 on 3 Jul 2026, Sudeep Pharma Ltd has demonstrated robust price momentum, supported by a confluence of technical indicators signalling sustained strength across multiple timeframes.

Extending its recent gains, Sudeep Pharma Ltd touched an intraday high of Rs 880.75 on 3 Jul 2026, marking a fresh all-time peak just shy of its 52-week high of Rs 883.20. This milestone caps a remarkable run that has seen the stock outperform its sector and the broader market by wide margins over multiple timeframes.

Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a marginal dip in daily price, the stock’s broader technical indicators reveal a complex interplay of signals that investors should carefully analyse amid its strong year-to-date returns.

Sudeep Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was assigned on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 30 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sudeep Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was assigned on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Surging past its previous peaks, Sudeep Pharma Ltd touched a new 52-week high of Rs 874.75 on 17 Jun 2026, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Extending its winning streak to four consecutive sessions, Sudeep Pharma Ltd surged to a fresh all-time high of Rs 860.55 on 17 Jun 2026, outperforming its sector and the broader market by a wide margin.

Surging past its previous peaks, Sudeep Pharma Ltd touched a fresh 52-week high of Rs 857.1 on 16 Jun 2026, marking a significant milestone in its price momentum. This breakout comes after a sustained three-day rally delivering nearly 15% returns, underscoring the stock’s robust technical positioning amid a cautiously optimistic market backdrop.

Extending its winning streak to three consecutive sessions, Sudeep Pharma Ltd surged to a fresh all-time high of Rs 856.1 on 16 Jun 2026, outperforming its sector and the broader market with a notable 1.58% gain on the day.

Surging to an intraday peak of Rs 820.7 on 15 Jun 2026, Sudeep Pharma Ltd has marked a fresh 52-week high, propelled by a confluence of robust technical signals and sustained price momentum that outpaced its sector peers.

Extending its recent rally, Sudeep Pharma Ltd surged 10.00% on 15 Jun 2026 to close at Rs 824.45, marking a fresh all-time high. This move outpaced the Sensex gain of 1.29% and reinforced the stock’s strong short-term momentum across multiple timeframes.

The Sensex gained 1.27% on 15 Jun 2026, yet Sudeep Pharma Ltd outpaced the broader market with an 8.99% surge, reaching an intraday high of Rs 796.55. This 6.86-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Sudeep Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has delivered its highest quarterly financial results to date in March 2026, marking a significant milestone in its operational performance. Despite this, the company’s overall financial trend has shifted from positive to flat, signalling a nuanced outlook for investors as the stock navigates a mixed market environment.

Sudeep Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.